Evidence map›Paper›PMID 42814333›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2027

Immunophenotyping by Single-Cell CITE-Seq.

Wilson Dos-Santos Bele, Sandra Curras-Alonso, Fabien Delahaye

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wilson Dos-Santos BeleTarget Disease and Systems Biology, Research and Development, Sanofi, Vitry, France.
Sandra Curras-AlonsoTarget Disease and Systems Biology, Research and Development, Sanofi, Vitry, France.
Fabien DelahayeTarget Disease and Systems Biology, Research and Development, Sanofi, Vitry, France. Fabien.delahaye@sanofi.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single-cell transcriptomics has revolutionized our understanding of cellular heterogeneity by enabling high-resolution gene expression profiling at the individual cell level. However, traditional single-cell RNA sequencing (scRNA-seq) lacks direct protein quantification, limiting comprehensive immunophenotyping. Cellular Indexing of Transcriptomes and Epitopes by sequencing (CITE-seq) overcomes this limitation by integrating antibody-derived tag (ADT) quantification with scRNA-seq, allowing simultaneous measurement of surface protein and gene expression from the same cell. This multimodal approach enhances immune cell characterization, revealing new functional states and rare subpopulations in complex biological systems. Here, we provide a detailed protocol for performing CITE-seq, from sample preparation to sequencing and data analysis. We highlight key experimental considerations, discuss challenges related to antibody selection and batch effects, and provide troubleshooting strategies to ensure robust and reproducible results. The integration of transcriptomic and proteomic data through CITE-seq provides unparalleled insights into cellular function, with broad applications in immunology, oncology, and systems biology.

Indexed as

ImmunophenotypingRNA-SeqSingle-Cell AnalysisAnimalsEpitopesGene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansProteomicsSequence Analysis, RNASingle-Cell Gene Expression AnalysisTranscriptomeEpitopesAntibody-derived tagsCellular heterogeneityCITE-seqHigh-throughput sequencingImmune cell characterizationImmunophenotypingMultimodal profilingSingle-cell proteomicsSingle-cell RNA sequencingTranscriptomics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.